Hypercalcemia Treatment Market By Drug Class (Bisphosphonates, Calcimimetic Agents, Calcitonin, Denusomab, Glucocorticoids) - Growth, Future Prospects & Competitive Analysis, 2018 - 2026

Industry Outlook

The global hypercalcemia treatment market will reach US$ 23,707.8 Mn by 2026 from US$ 9,544.1 Mn in 2017, growing at a CAGR of 10.7% during the forecast period from 2018 to 2026. Hypercalcemia is a condition characterized by the elevated levels of serum calcium ranging above 2.6 mmol/L. The disorder is predominantly associated with two main causes including hypercalcemia of malignancy (HCM) and primary hyperparathyroidism. The disorder occurs in 10% to 20% of the cancer patients, prominently in the breast and lung cancer patients. Furthermore, other factors responsible for hypercalcemia are hereditary factors, severe dehydration, medications, and supplements. The global hypercalcemia treatment market will surge during the forecast period pertaining to the rising number of cancer patients, growing prevalence of hyperparathyroidism-related hypercalcemia, and availability of appropriate drug treatment therapies. Furthermore, rising incidence of multiple myeloma, availability of drug therapy alternatives over surgeries and favorable reimbursement policies in developed countries including the United States expected to fuel global market.

As generics dominates the market, label extension of the drugs for the treatment of more indications further expected to contribute to the growth of the market. The key market players are particularly focusing on the chronic kidney disease (CKD) along with the parathyroidism. For instance, US FDA approved a drug manufactured by OPKO Health for the treatment of secondary hyperparathyroidism in adults with CKD. Such approvals will propel the growth of global hypercalcemia market.

Market Synopsis

Hypercalcemia Treatment Market

Get a sample copy for more information

Bisphosphonates expected to retain major market share during the forecast period

Bisphosphonates is the major segment capturing over 65% of market value share. Bisphosphonates are used to prevent the loss of bone density. Due to the high preference of bisphosphonates, the segment will retain its supremacy in the market during the forecast period. Furthermore, the usage of combination therapy for the treatment of hypercalcemia is increasing, which combines two or more drugs from same or different classes. The high preference of combination therapy in developed country further fuels the growth of bisphosphonates market as these drugs are used predominantly in combination therapy with other drugs and therapies. For instance, many researchers and physicians are evaluating the use of combination of pamidronate and calcitonin. Denusomab market segment will be the fastest growing market segment during the forecast period followed by calcitonin. The aforementioned treatment pattern adopted by physicians is expected to catalyze the growth of hypercalcemia drugs market.

Hypercalcemia Treatment Market

Get a sample copy for more information

Asia Pacific to Experience Lucrative Growth with Double Digit CAGR during the Forecast Period

The Asia Pacific expected to witness lucrative growth during the forecast period owing to high awareness and rising adoption of the hypercalcemia treatment drugs. Furthermore, increasing prevalence of hyperparathyroidism-related hypercalcemia and growing incidence of multiple myeloma in the region expected to fuel the market. Additionally, the rising accessibility of drug therapies and favorable reimbursement policies in the developing countries further contributes to the double-digit growth of the Asia Pacific market.

In 2017, North America dominated the hypercalcemia treatment market with over 34% of the market share, in terms of market value. The United States expected to dominate the North America market due to high awareness regarding hypercalcemia and associated disorders. Furthermore, growing prevalence of malignancy-related hypercalcemia among cancer patients will further catalyze the growth of the North America hypercalcemia market.

Hypercalcemia Treatment Market

Get a sample copy for more information

Approval of Promising Pipeline Candidates Expected to Fuel the Market Growth

The global hypercalcemia treatment market is highly fragmented due to the presence of numerous players. However, some of the players dominated the market attributing to the development of effective drugs, novel product launches, and strategic market initiatives. Furthermore, the unmet needs of the disease compel manufacturers to focus on R&D and develop products that are more efficient. For instance, Kyowa Hakko Kirin Co., Ltd. has completed phase III clinical trials for KHK7580 and filled a NDA (New Drug Application) in Japan. Furthermore, the manufacturers is developing another candidate, KRN1493, for secondary hyperparathyroidism. Expected approval of such promising candidates will fuel the market during the forecast period. Additionally, key players in hypercalcemia market include Novartis AG, Amgen, Inc., Teva Pharmaceuticals Industries Ltd., F.Hoffmann-La Roche Ltd., Kyowa Hakko Kirin, OPKO Health, Merck & Co., Abbive, Inc., and Pfizer, Inc.

Hypercalcemia Treatment Market

Historical & Forecast Period

The hypercalcemia market is scrutinized considering 2017 as the base year for the research and CAGRs are calculated for the forecast period from 2018 to 2026.

Report Scope by Segments

This holistic research study on hypercalcemia treatment market present the current market dynamics and outlook. The research study is conducted at granular level by segmenting the market in terms of drug class and geography.

Research Period  2016-2026
Base Year 2017
Forecast Period  2018-2026
Historical Year  2016
Unit  USD Million

 Drug Class Segment (2016–2026; US$ Mn)
 • Bisphosphonates
   o Clodronate
   o Etidronate
   o Ibandronate
   o Pamidronate
   o Zoledronic acid
 • Calcitonin
 • Glucocorticoids
 • Calcimimetic agents
 • Denusomab
 • Pipeline Analysis
   o Phase III (Market Estimations up to 2026)
      KHK7580
   o Phase II & I (Qualitative Information)

 Geography Segment (2016–2026; US$ Mn)
 • North America (U.S., Canada)
 • Europe (U.K., Germany, Rest of Europe)
 • Asia Pacific (Japan, China, Rest of APAC)
 • Latin America (Brazil, Mexico, Rest of LATAM)
 • Middle East and Africa (GCC, Rest of MEA)

This research study further elucidates the key qualitative market assessment parameters including key market trends, DROs, to assist in holistic understanding of global hypercalcemia treatment market. Additionally, the major players are mapped graphically based on their business strength, market strategies and product offering. The research study further provides attractive investment proposition based on the extensive geographical research. Major manufacturers profiled in the report include AbbVie, Inc., Merck & Co., OPKO Health, Novartis AG, Amgen, Inc., Teva Pharmaceuticals Industries Ltd., F.Hoffmann-La Roche Ltd., Kyowa Hakko Kirin and Pfizer, Inc.

Choose License Type
Trusted By
Published Date:  Apr 2018
Category:  Pharmaceuticals
Report ID:   59106
Report Format:   PDF
Pages:   120
Rating:    4.5 (70)
Delivery Time: 24 Hours to 48 Hours   
Connect With Us
24/7 Research Support